WHO WE ARE
Glycologix is an innovative biotechnology company developing a platform of proprietary, locally delivered biopolymers for the protection and repair of soft tissues.
WHAT WE DO
Our compounds mimic natural proteoglycans (PGs); complex biopolymers found in healthy soft tissue that serve critical biologic functions: hydration, structural support, and lubrication.
HOW WE HELP
Our broadly applicable biopolymer platform can be tailored to address multiple large unmet medical needs, such as interstitial cystitis / bladder pain syndrome (IC / BPS), dry eye, surgical adhesion prevention, osteoarthritis, disk disease and wound repair.
Dan has over 25 years in biopharma development and commercialization. His broad global experience spans all stages of biomedical development across multiple platforms including biomaterials, small molecules and cell therapy.
Previous to his CEO position at Glycologix, Dan was a trusted leader and builder of world-class teams at Genzyme and Flexion Therapeutics. Dan founded the Flexion commercial organization and built the team which architected the successful launch Flexion’s flagship product Zilretta®, while partnering with the CEO and CFO to raise nearly $600M in follow-on equity and convertible debt offerings. At Genzyme, Dan held a variety of leadership positions across several functions. Dan has an MBA from the Wharton School of Management at the University of Pennsylvania and B.S. in Biochemistry.
Rich Heidebracht, PhD
VP, Research + Development
Rich is an organic chemist and a scientific leader in biotechnology organizations with a strong track record of recruiting, managing, and collaborating with multidisciplinary teams. Rich is an expert in the areas of medicinal, process, and analytical chemistry; experienced in drug delivery, polymer chemistry, macromolecular conjugations, formulation, surface chemistry, regulatory affairs, operations and computer-assisted discovery. He has over 17 yrs. in therapeutics and devices, at institutions and companies including the Broad Institute, Merck, Pfizer and Sigalon. Rich is the author on 33 patents and 15 peer-reviewed papers and an invited speaker on diverse subjects.
George is a serial entrepreneur having been a co-founder of 14+ technology startups in diverse markets: aerospace, building controls, as well as 8 medical devices companies. He co-founded Axya Medical, sold to Tornier, Palomar Medical Technologies acquired by Cynosure, Andover Controls, sold to Schneider, and Concert Medical, sold to Galt Medical Corp. He has been involved in 2 IPOs and 4 M&A exits.He has served as Chairman, CEO, President, as well as numerous operational roles.
Tom is a seasoned R&D leader and inventor with a distinguished and diverse 30-year career in medicinal chemistry, biomaterials, drug delivery and polymer science. Currently, Tom serves as Cofounder and CSO at Glyscend Inc. His earlier leadership roles included: VP Biomaterials Science & Engineering at Genzyme Corp, and Senior Director at GelTex Pharmaceuticals. Tom has also held industrial research positions at Eastman Kodak, and General Electric.
Grannum Sant, MD, FRCS, FACS
Grannum is an internationally renowned physician and scientist with a distinguished >30-year career in medicine, in both academia and industry. He has led many organizations in the areas of Urology and Oncology. He served as chairman of the department and held an endowed Professorship at Tufts University School of Medicine Department of Urology. Dr. Sant has held numerous leadership positions within research and professional societies, including a term as President of the New England Section of the American Urological Association. He is the originator of the widely accepted O’Leary-Sant interstitial cystitis symptom index.
In his time in industry, he has held numerous senior roles including; Senior Director, VP and Head, or Medical Director at OPKO Health, Genzyme, Sanofi US, Sanofi Aventis, and Sanofi Synthelabo.
Robert Hurst, PhD
Bob is an internationally recognized biochemist with expertise in malignant and nonmalignant urologic diseases, mostly of the bladder. He is an emeritus professor in the Department of Urology at the University of Oklahoma Health Sciences Center College of Medicine, where he directed the Systems Biology Program and the Department of Urology Basic Research Program. Of his 157 peer-reviewed scientific publications, 43 were in the field of IC/BPS, bladder inflammation or regeneration. Dr. Hurst is also an experienced entrepreneur, having been President and Chief Scientific Officer for DormaTarg, a startup in the cancer therapeutic space.
Carol has more than 40 years of industry experience in negotiating biotech and medtech licensing and acquisition transactions. She has held leadership positions at General Electric Life Sciences, Eagle-Picher Chemsyn and Genzyme as well as on the executive teams at Pronota NV, Spark Therapeutics and Quad Technologies.
Eugene Skrabut, MS
Gene has extensive product research and development experience in the fields of regenerative medicine, bioresorbable medical devices, and biotechnology. His leadership has led to the approval of several products including collagen-based artificial skin (marketed as Integra®), hyaluronate-based adhesion barriers (marketed as Sepra®film) and viscosupplements (marketed as Synvisc® and Jonexa™), biomaterials for cartilage regenerative matrix delivered cell therapy (marketed as MACI®), and skin regenerative cell therapy (marketed as Epicel®).